Immunotherapeutic restoration in HIV-infected individuals

Immunotherapy

Volumn 3, Issue 2, 2011, Pages 247-267

  Kim, June Myung ^a   Han, Sang Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

cytokine therapy; HIV; immune modulating drugs; immunotherapy; monoclonal antibodies; nanotechnology based approaches; radioimmunotherapy; therapeutic immunization

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOSPORIN A; CYT 99007; DIDANOSINE; ENFUVIRTIDE; HRG 214; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROXYUREA; IBALIZUMAB; IMMUNOGLOBULIN G ANTIBODY; IMMUNOMODULATING AGENT; MACROPHAGE ACTIVATING FACTOR; MINOCYCLINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F 105; MONOCLONAL ANTIBODY HGS 004; MONOCLONAL ANTIBODY KD 247; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEPTIDE VACCINE; PHOSPHOLIPID ANTIBODY; PLACEBO; PRO 140; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 7; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUTI 16; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC;

BINDING AFFINITY; CAPILLARY LEAK SYNDROME; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; COMBINED ACTIVE ANTIRETROVIRAL THERAPY; CONTINUOUS INFUSION; CROSS RESISTANCE; DEEP VEIN THROMBOSIS; DENDRITIC CELL; DRUG BLOOD LEVEL; DRUG COMBINATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HGS 004; HYPERBILIRUBINEMIA; IC 50; IMMUNE RESPONSE; IMMUNOTHERAPY; LOW DRUG DOSE; MENTAL DISEASE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYALGIA; NANOTECHNOLOGY; NONHUMAN; PANCREAS DISEASE; PANCREAS TOXICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHOCK; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY;

EID: 79951741375     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.91     Document Type: Review

References (176)

1. Palella FJ Jr, Baker RK, Moorman AC et al.: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr. 43(1), 27-34 (2006). (Pubitemid 44306484)
2. Pett SL, Kelleher AD: Cytokine therapies in HIV-1 infection: present and future. Expert Rev. Anti Infect. Ther. 1(1), 83-96 (2003). (Pubitemid 38735732)
3. Rinaldo CR: Dendritic cell-based human immunodeficiency virus vaccine. J. Intern. Med. 265(1), 138-158 (2009).
4. Bourinbaiar AS, Root-Bernstein RS, Abulafia-Lapid R et al.: Therapeutic AIDS vaccines. Curr. Pharm. Des. 12(16), 2017-2030 (2006). (Pubitemid 43821690)
5. Redel L, Le Douce V, Cherrier T et al.: HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. J. Leukoc. Biol. 87(4), 575-588 (2010).
6. Sodora DL, Silvestri G: Immune activation and AIDS pathogenesis. AIDS 22(4), 439-446 (2008). (Pubitemid 351317285)
7. Albuquerque AS, Foxall RB, Cortesao CS et al.: Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease. Clin. Immunol. 125(1), 67-75 (2007). (Pubitemid 47376925)
8. Marziali M, De Santis W, Carello R et al.: T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 20(16), 2033-2041 (2006). (Pubitemid 44611056)
9. Aiuti F, Mezzaroma I: Failure to reconstitute CD4+ T cells despite suppression of HIV replication under HAART. AIDS Rev. 8(2), 88-97 (2006). (Pubitemid 44043557)
10. Smith KA: Interleukin-2: inception, impact and implications. Science 240(4856), 1169-1176 (1988).
11. Lin SJ, Roberts RL, Ank BJ, Nguyen QH, Thomas EK, Stiehm ER: Human immunodeficiency virus (HIV) type-1 gP120- specific cell-mediated cytotoxicity (CMC) and natural killer (NK) activity in HIV-infected (HIV+) subjects: enhancement with interleukin-2 (IL-2), IL-12 and IL-15. Clin. Immunol. Immunopathol. 82(2), 163-173 (1997). (Pubitemid 27072896)
12. Liegler TJ, Stites DP: HIV-1 gp120 and anti-gp120 induce reversible unresponsiveness in peripheral CD4 T lymphocytes. J. Acquir. Immune Defic. Syndr. 7(4), 340-348 (1994).
13. Read SW, Lempicki RA, Di Mascio M et al.: CD4 T-cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T-cell count of HIV-infected patients. J. Infect. Dis. 198(6), 843-850 (2008).
14. Sereti I, Sklar P, Ramchandani MS et al.: CD4+ T-cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. J. Infect. Dis. 196(5), 677-683 (2007). (Pubitemid 47293848)
15. Levy Y, Durier C, Krzysiek R et al.: Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 17(3), 343-351 (2003). (Pubitemid 36223259)
16. Arduino RC, Nannini EC, Rodriguez-Barradas M et al.: CD4 cell response to three doses of subcutaneous interleukin-2: meta-analysis of three Vanguard studies. Clin. Infect. Dis. 39(1), 115-122 (2004). (Pubitemid 38879558)
17. Stellbrink HJ, van Lunzen J, Westby M et al.: Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 16(11), 1479-1487 (2002). (Pubitemid 34804212)
18. Henry K, Katzenstein D, Cherng DW et al.: A pilot study evaluating time to CD4 T-cell count less than 350 cells/mm3 after treatment interruption following antiretroviral therapy interleukin 2: results of ACTG A5102. J. Acquir. Immune Defic. Syndr. 42(2), 140-148 (2006). (Pubitemid 43884707)
19. Katlama C, Carcelain G, Duvivier C et al.: Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study- ANRS 082. AIDS 16(15), 2027-2034 (2002). (Pubitemid 35205266)
20. Delaugerre C, Gourlain K, Tubiana R et al.: Increase of HIV-1 proviral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4 (Pubitemid 36960897)
21. de Boer AW, Markowitz N, Lane HC et al.: A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells. Clin. Immunol. 106(3), 188-196 (2003). (Pubitemid 36428990)
22. Levy Y, Capitant C, Houhou S et al.: Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomized controlled trial. ANRS 048 study group. Lancet 353(9168), 1923-1929 (1999). (Pubitemid 29255705)
23. Carr A, Emery S, Lloyd A et al.: Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group. J. Infect. Dis. 178(4), 992-999 (1998). (Pubitemid 28452190)
24. Arno A, Ruiz L, Juan M et al.: Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load. J. Infect. Dis. 180(1), 56-60 (1999). (Pubitemid 29293917)
25. Marchetti G, Meroni L, Varchetta S et al.: Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J. Infect. Dis. 186(5), 606-616 (2002). (Pubitemid 34925532)
26. Tambussi G, Ghezzi S, Nozza S et al.: Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. J. Infect. Dis. 183(10), 1476-1484 (2001). (Pubitemid 32421600)
27. Ruxrungtham K, Suwanagool S, Tavel JA et al.: A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. AIDS 14(16), 2509-2513 (2000).
28. Losso MH, Belloso WH, Emery S et al.: A randomized, controlled, Phase II trial comparing escalating doses of subcutaneous IL-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts ≥350/mm3. J. Infect. Dis. 181(5), 1614-1621 (2000). (Pubitemid 30387752)
29. Abrams DI, Bebchuk JD, Denning ET et al.: Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of ≥300/mm3: CPCRA 059. J. Acquir. Immune Defic. Syndr. 29(3), 221-231 (2002). (Pubitemid 34208530)
30. Miller KD, Spooner K, Herpin BR et al.: Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T lymphocyte expansion. Clin. Immunol. 99(1), 30-42 (2001).
31. Durier C, Capitant C, Lascaux AS et al.: Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials). Aids 21(14), 1887-1897 (2007). (Pubitemid 47329765)
32. Abrams D, Levy Y, Losso MH et al.: Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 361(16), 1548-1559 (2009).
33. Lalezari JP, Beal JA, Ruane PJ et al.: Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial. HIV Clin. Trials 1(3), 1-15 (2000).
34. Mitsuyasu R, Gelman R, Cherng DW et al.: The virologic, immunologic and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial - AIDS Clinical Trials Group 328. Arch. Intern. Med. 167(6), 597-605 (2007) (Pubitemid 46513230)
35. Davey RT Jr, Murphy RL, Graziano FM et al.: Immunologic and virologic effects of subcutaneous interleukin-2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 284(2), 183-189 (2000). (Pubitemid 30460861)
36. Davey RT Jr, Chaitt DG, Albert JM et al.: A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J. Infect. Dis. 179(4), 849-858 (1999). (Pubitemid 29159330)
37. Kovacs JA, Vogel S, Albert JM et al.: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335(18), 1350-1356 (1996). (Pubitemid 26360453)
38. Kovacs JA, Baseler M, Dewar RJ et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 332(9), 567-575 (1995).
39. Fry TJ, Connick E, Falloon J et al.: A potential role for interleukin-7 in T-cell homeostasis. Blood 97(10), 2983-2990 (2001).
40. Fry TJ, Moniuszko M, Creekmore S et al.: IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 101(6), 2294-2299 (2003). (Pubitemid 36302072)
41. Beq S, Nugeyre MT, Ho Tsong Fang R et al.: IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J. Immunol. 176(2), 914-922 (2006). (Pubitemid 43099689)
42. Storek J, Gillespy T 3rd, Lu H et al.: Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood 101(10), 4209-4218 (2003). (Pubitemid 36857906)
43. Fry TJ, Mackall CL: Interleukin-7: from bench to clinic. Blood 99(11), 3892-3904 (2002). (Pubitemid 35332024)
44. Rosenberg SA, Sportes C, Ahmadzadeh M et al.: IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 29(3), 313-319 (2006). (Pubitemid 44297299)
45. Sportes C, Hakim FT, Memon SA et al.: Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T-cell subsets. J. Exp. Med. 205(7), 1701-1714 (2008). (Pubitemid 351962032)
46. Interim data released from INSPIRE study on interleukin-7. AIDS Patient Care STDS 23(11), 987-988 (2009).
47. Levy Y: Effects of r-hIL-7 on T-cell recovery and thymic output in HIV-infected patients receiving c-ART; interim analysis of a Phase I/IIa multicenter study. Presented at: 49th ICAAC, San Francisco, CA, USA 12-15 September 2009.
48. Elsaesser H, Sauer K, Brooks DG: IL-21 is required to control chronic viral infection. Science 324(5934), 1569-1572 (2009).
49. Yi JS, Du M, Zajac AJ: A vital role for interleukin-21 in the control of a chronic viral infection. Science 324(5934), 1572-1576 (2009).
50. Frohlich A, Kisielow J, Schmitz I et al.: IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324(5934), 1576-1580 (2009).
51. Wei L, Laurence A, Elias KM, OShea JJ: IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J. Biol. Chem. 282(48), 34605-34610 (2007). (Pubitemid 350232469)
52. Yang L, Anderson DE, Baecher-Allan C et al.: IL-21 and TGF-b are required for differentiation of human T(h)17 cells. Nature 454(7202), 350-352 (2008).
53. Suto A, Kashiwakuma D, Kagami S et al.: Development and characterization of IL-21-producing CD4+ T cells. J. Exp. Med. 205(6), 1369-1379 (2008). (Pubitemid 351831493)
54. Peluso I, Fantini MC, Fina D et al.: IL-21 counteracts the regulatory T-cell mediated suppression of human CD4+ T lymphocytes. J. Immunol. 178(2), 732-739 (2007). (Pubitemid 46095145)
55. Iannello A, Tremblay C, Routy JP, Boulassel MR, Toma E, Ahmad A: Decreased levels of circulating IL-21 in HIV-infected AIDS patients: correlation with CD4+ T-cell counts. Viral Immunol. 21(3), 385-388 (2008).
56. Iannello A, Boulassel MR, Samarani S et al.: Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J. Immunol. 184(1), 114-126 (2010).
57. Yamamoto N, Ushijima N, Koga Y: Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). J. Med. Virol. 81(1), 16-26 (2009).
58. Yamamoto N: Pathogenic significance of a-N-acetylgalactosaminidase activity found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 22(3), 262-271 (2006).
59. Yamamoto N, Naraparaju VR, Srinivasula SM: Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients. AIDS Res. Hum. Retroviruses 11(11), 1373-1378 (1995).
60. Salk J: Prospects for the control of AIDS by immunizing seropositive individuals. Nature 327(6122), 473-476 (1987). (Pubitemid 17085816)
61. Sommerfelt MA, Sorensen B: Prospects for HIV-1 therapeutic immunisation and vaccination: the potential contribution of peptide immunogens. Expert Opin. Biol. Ther. 8(6), 745-757 (2008). (Pubitemid 351860204)
62. Douek DC, Brenchley JM, Betts MR et al.: HIV preferentially infects HIV-specific CD4+ T cells. Nature 417(6884), 95-98 (2002). (Pubitemid 34498823)
63. Barouch DH, Santra S, Schmitz JE et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290(5491), 486-492 (2000).
64. Barouch DH, Fu TM, Montefiori DC, Lewis MG, Shiver JW, Letvin NL: Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol. Lett. 79(1-2), 57-61 (2001). (Pubitemid 32938208)
65. Boyer JD, Robinson TM, Kutzler MA et al.: Protection against simian/human immunodeficiency virus (SHIV)89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc. Natl Acad. Sci. USA 104(47), 18648-18653 (2007). (Pubitemid 350210751)
66. Nacsa J, Edghill-Smith Y, Tsai WP et al.: Contrasting effects of low-dose IL-2 on vaccine-boosted simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cells in macaques chronically infected with SIVmac251. J. Immunol. 174(4), 1913-1921 (2005). (Pubitemid 40223931)
67. Chong SY, Egan MA, Kutzler MA et al.: Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 25(26), 4967-4982 (2007). (Pubitemid 46843429)
68. Ahuja SS, Reddick RL, Sato N et al.: Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J. Immunol. 163(7), 3890-3897 (1999). (Pubitemid 29450916)
69. Ozawa H, Ding W, Torii H et al.: Granulocyte-macrophage colony-stimulating factor gene transfer to dendritic cells or epidermal cells augments their antigen-presenting function including induction of anti-tumor immunity. J. Invest. Dermatol. 113(6), 999-1005 (1999). (Pubitemid 30013344)
70. Takayama T, Tahara H, Thomson AW: Transduction of dendritic cell progenitors with a retroviral vector encoding viral interleukin-10 and enhanced green fluorescent protein allows purification of potentially tolerogenic antigen-presenting cells. Transplantation 68(12), 1903-1909 (1999). (Pubitemid 30027345)
71. Melero I, Duarte M, Ruiz J et al.: Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther. 6(10), 1779-1784 (1999). (Pubitemid 29485955)
72. Lu W, Arraes LC, Ferreira WT, Andrieu JM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10(12), 1359-1365 (2004). (Pubitemid 40022718)
73. Lu W, Wu X, Lu Y, Guo W, Andrieu JM: Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9(1), 27-32 (2003). (Pubitemid 36098256)
74. Romani N, Gruner S, Brang D et al.: Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180(1), 83-93 (1994). (Pubitemid 24181058)
75. Nicolette CA, Healey D, Tcherepanova I et al.: Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 25(Suppl. 2), B47-B60 (2007). (Pubitemid 47488550)
76. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA: Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin. Vaccine Immunol. 15(2), 284-292 (2008). (Pubitemid 352025534)
77. Kundu SK, Engleman E, Benike C et al.: A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res. Hum. Retroviruses 14(7), 551-560 (1998). (Pubitemid 28196782)
78. Shapero MH, Kundu SK, Engleman E, Laus R, van Schooten WC, Merigan TC: In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients. Cell Transplant. 9(3), 307-317 (2000). (Pubitemid 30655683)
79. Garcia F, Lejeune M, Climent N et al.: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 191(10), 1680-1685 (2005). (Pubitemid 40656756)
80. Ide F, Nakamura T, Tomizawa M et al.: Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a Phase I trial. J. Med. Virol. 78(6), 711-718 (2006).
81. Dezube BJ, Proper J, Zhang J et al.: A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a Phase I study. J. Infect. Dis. 187(3), 500-503 (2003). (Pubitemid 36184592)
82. Pett SL, Williams LA, Day RO et al.: A Phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals. HIV Clin. Trials 5(2), 91-98 (2004). (Pubitemid 38697084)
83. Verity EE, Williams LA, Haddad DN et al.: Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody. AIDS 20(4), 505-515 (2006). (Pubitemid 43731594)
84. Goldstein G, Chicca JJ 2nd: A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting. Vaccine 28(4), 1008-1014 (2010).
85. Song R, Franco D, Kao CY, Yu F, Huang Y, Ho DD: Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J. Virol. 84(14), 6935-6942 (2010).
86. Reimann KA, Khunkhun R, Lin W, Gordon W, Fung M: A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 18(11), 747-755 (2002).
87. Merkenschlager M, Buck D, Beverley PC, Sattentau QJ: Functional epitope analysis of the human CD4 molecule. The MHC class II-dependent activation of resting T cells is inhibited by monoclonal antibodies to CD4 regardless whether or not they recognize epitopes involved in the binding of MHC class II or HIV gp120. J. Immunol. 145(9), 2839-2845 (1990). (Pubitemid 20382550)
88. Jacobson JM, Kuritzkes DR, Godofsky E et al.: Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 53(2), 450-457 (2009).
89. Kuritzkes DR, Jacobson J, Powderly WG et al.: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189(2), 286-291 (2004). (Pubitemid 38147253)
90. Zhang XQ, Sorensen M, Fung M, Schooley RT: Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob. Agents Chemother. 50(6), 2231-2233 (2006). (Pubitemid 43807552)
91. Norris D MJ, Gathe J et al.: Phase II efficacy and safety of the novel entry inhibitor, TNX-355, in combination with optimized background regimen (OBR). Presented at: Sixteenth International AIDS Conference, Toronto, ON, Canada 13-18 August 2006.
92. Boon L, Holland B, Gordon W et al.: Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in nonhuman primates. Toxicology 172(3), 191-203 (2002). (Pubitemid 34219385)
93. Eda Y, Takizawa M, Murakami T et al.: Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J. Virol. 80(11), 5552-5562 (2006).
94. Gorny MK, Williams C, Volsky B et al.: Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 76(18), 9035-9045 (2002). (Pubitemid 34919862)
95. Gorny MK, Revesz K, Williams C et al.: The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J. Virol. 78(5), 2394-2404 (2004). (Pubitemid 38228932)
96. Matsushita S, Takahama S, Shibata J et al.: Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247. Hum. Antibodies 14(3-4), 81-88 (2005).
97. Murakami T, Eda Y, Nakasone T et al.: Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS 23(12), 1485-1494 (2009).
98. Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, Matsushita S: Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J. Virol. 81(8), 3757-3768 (2007). (Pubitemid 46586873)
99. Eda Y, Murakami T, Ami Y et al.: Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J. Virol. 80(11), 5563-5570 (2006).
100. Hatada M, Yoshimura K, Harada S, Kawanami Y, Shibata J, Matsushita S: Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J. Gen. Virol. 91(Pt 5), 1335-1345 (2010).
101. Yoshimura K, Shibata J, Kimura T et al.: Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 20(16), 2065-2073 (2006). (Pubitemid 44611059)
102. Steinberger P, Sutton JK, Rader C, Elia M, Barbas CF 3rd: Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J. Biol. Chem. 275(46), 36073-36078 (2000).
103. Blanpain C, Vanderwinden JM, Cihak J et al.: Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol. Biol. Cell. 13(2), 723-737 (2002). (Pubitemid 34165096)
104. Ji C, Brandt M, Dioszegi M et al.: Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Res. 74(2), 125-137 (2007). (Pubitemid 46442746)
105. Whitcomb JM, Huang W, Fransen S et al.: Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51(2), 566-575 (2007). (Pubitemid 46185274)
106. Binley JM, Wrin T, Korber B et al.: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78(23), 13232-13252 (2004). (Pubitemid 39507829)
107. Richman DD, Wrin T, Little SJ, Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100(7), 4144-4149 (2003). (Pubitemid 36418171)
108. Rusert P, Kuster H, Joos B et al.: Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J. Virol. 79(13), 8454-8469 (2005). (Pubitemid 40853547)
109. Trkola A, Ketas TJ, Nagashima KA et al.: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75(2), 579-588 (2001). (Pubitemid 32037260)
110. Cilliers T, Nhlapo J, Coetzer M et al.: The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J. Virol. 77(7), 4449-4456 (2003). (Pubitemid 36350986)
111. Shearer WT, DeVille JG, Samson PM et al.: Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140). J. Allergy Clin. Immunol. 118(2), 518-521 (2006). (Pubitemid 44142701)
112. Lalezari J, Yadavalli GK, Para M et al.: Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J. Infect. Dis. 197(5), 721-727 (2008). (Pubitemid 351364473)
113. Jacobson JM, Saag MS, Thompson MA et al.: Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J. Infect. Dis. 198(9), 1345-1352 (2008).
114. Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC: Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 50(10), 3289-3296 (2006). (Pubitemid 44527500)
115. Jacobson JM, Thompson MA, Lalezari JP et al.: Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J. Infect. Dis. 201(10), 1481-1487 (2010).
116. Jacobson JM, Lalezari JP, Thompson MA et al.: Phase IIa study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob. Agents Chemother. 54(10), 4137-4142 (2010).
117. Roschke V CS, Branco L et al.: Characterization of a panel of novel human monoclonal antibodies that specially antagonize CCR5 and block HIV entry. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA 30 October-2 November 2004, (Abstract H-213).
118. Marozsan AJ, Kuhmann SE, Morgan T et al.: Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338(1), 182-199 (2005). (Pubitemid 40835936)
119. Tsibris AM, Sagar M, Gulick RM et al.: In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 82(16), 8210-8214 (2008).
120. Pugach P, Ketas TJ, Michael E, Moore JP: Neutralizing antibody and antiretroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 377(2), 401-407 (2008).
121. Ji C, Zhang J, Dioszegi M et al.: CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor. Mol. Pharmacol. 72(1), 18-28 (2007). (Pubitemid 46998521)
122. Brown BK, Karasavvas N, Beck Z et al.: Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J. Virol. 81(4), 2087-2091 (2007). (Pubitemid 46214483)
123. Moody MA, Liao HX, Alam SM et al.: Antiphospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce b-chemokines. J. Exp. Med.
124. Burton DR, Stanfield RL, Wilson IA: Antibody vs HIV in a clash of evolutionary titans. Proc. Natl Acad. Sci. USA 102(42), 14943-14948 (2005). (Pubitemid 41513316)
125. Cavacini LA, Samore MH, Gambertoglio J et al.: Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 14(7), 545-550 (1998). (Pubitemid 28196781)
126. Song E, Zhu P, Lee SK et al.: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23(6), 709-717 (2005). (Pubitemid 41716361)
127. Clayton R, Ohagen A, Goethals O et al.: Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1k monoclonal antibody, in HIV-1 infected cells. J. Virol. Methods 139(1), 17-23 (2007). (Pubitemid 44854219)
128. Coutinho A: Beyond clonal selection and network. Immunol. Rev. 110, 63-87 (1989). (Pubitemid 19216009)
129. Haynes BF, Fleming J, St Clair EW et al.: Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308(5730), 1906-1908 (2005). (Pubitemid 40941873)
130. Preece AF, Strahan KM, Devitt J, Yamamoto F, Gustafsson K: Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement. Blood 99(7), 2477-2482 (2002). (Pubitemid 34525435)
131. Metlas R, Srdic T, Veljkovic V: Anti-IgG antibodies from sera of healthy individuals neutralize HIV-1 primary isolates. Curr. HIV Res. 5(2), 261-265 (2007). (Pubitemid 46488201)
132. Scheid JF, Mouquet H, Feldhahn N et al.: Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458(7238), 636-640 (2009).
133. Metlas RM, Srdic TV, Jenabian MA et al.: Immunoglobulin G-reactive antibodies from sera of healthy individuals enriched in IgG2-therapeutic potential in HIV-1 infection. Curr. HIV Res. 7(4), 378-383 (2009).
134. McCune JM: The dynamics of CD4+ T-cell depletion in HIV disease. Nature. 410(6831), 974-979 (2001). (Pubitemid 32335848)
135. Brenchley JM, Price DA, Schacker TW et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12(12), 1365-1371 (2006). (Pubitemid 44924494)
136. Lori F, Foli A, Groff A et al.: Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic (virostatic) mechanisms. AIDS 19(11), 1173-1181 (2005). (Pubitemid 41059258)
137. Lori F, Malykh A, Cara A et al.: Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266(5186), 801-805 (1994). (Pubitemid 24359288)
138. Lisziewicz J, Foli A, Wainberg M, Lori F: Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns. Drug Saf. 26(9), 605-624 (2003). (Pubitemid 36871835)
139. Lori F, Foli A, Maserati R et al.: Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T-cell responses. HIV Clin. Trials 3(2), 115-124 (2002). (Pubitemid 34520988)
140. Lova L, Groff A, Ravot E et al.: Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes. AIDS 19(2), 137-144 (2005). (Pubitemid 40409532)
141. Lopez M, Benito JM, Lozano S et al.: Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea. AIDS 18(9), 1251-1261 (2004). (Pubitemid 38822703)
142. Havlir DV, Gilbert PB, Bennett K et al.: Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 15(11), 1379-1388 (2001). (Pubitemid 32662289)
143. Chapuis AG, Paolo Rizzardi G, DAgostino C et al.: Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat. Med. 6(7), 762-768 (2000). (Pubitemid 30469424)
144. Hossain MM, Coull JJ, Drusano GL, Margolis DM: Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine and tenofovir. Antiviral Res. 55(1), 41-52 (2002). (Pubitemid 34655641)
145. Coull JJ, Turner D, Melby T, Betts MR, Lanier R, Margolis DM: A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J. Acquir. Immune Defic. Syndr. 26(5), 423-434 (2001). (Pubitemid 32489020)
146. Margolis DM, Kewn S, Coull JJ et al.: The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J. Acquir. Immune Defic. Syndr. 31(1), 45-49 (2002).
147. Rizzardi GP, Harari A, Capiluppi B et al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J. Clin. Invest. 109(5), 681-688 (2002). (Pubitemid 34204847)
148. Zink MC, Suryanarayana K, Mankowski JL et al.: High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J. Virol. 73(12), 10480-10488 (1999).
149. Szeto GL, Brice AK, Yang HC, Barber SA, Siliciano RF, Clements JE: Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J. Infect. Dis. 201(8), 1132-1140 (2010).
150. Jenwitheesuk E, Samudrala R: Identification of potential HIV-1 targets of minocycline. Bioinformatics 23(20), 2797-2799 (2007). (Pubitemid 350048348)
151. Zink MC, Uhrlaub J, DeWitt J et al.: Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293(16), 2003-2011 (2005). (Pubitemid 40570894)
152. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR: Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81(17), 9249-9258 (2007). (Pubitemid 47311467)
153. Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M: PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am. J. Transplant. 8(7), 1486-1497 (2008). (Pubitemid 351989503)
154. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z: PD-1 upregulation is associated with HBV-specific T-cell dysfunction in chronic hepatitis B patients. Mol. Immunol. 45(4), 963-970 (2008). (Pubitemid 350019503)
155. Day CL, Kaufmann DE, Kiepiela P et al.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109), 350-354 (2006). (Pubitemid 44435155)
156. Trautmann L, Janbazian L, Chomont N et al.: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12(10), 1198-1202 (2006). (Pubitemid 44527357)
157. Velu V, Titanji K, Zhu B et al.: Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458(7235), 206-210 (2009).
158. Berger R, Rotem-Yehudar R, Slama G et al.: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044-3051 (2008).
159. Franceschini D, Paroli M, Francavilla V et al.: PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. 119(3), 551-564 (2009).
160. Blackburn SD, Shin H, Haining WN et al.: Coregulation of CD8+ T-cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10(1), 29-37 (2009).
161. Tacken PJ, de Vries IJ, Torensma R, Figdor CG: Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790-802 (2007). (Pubitemid 47480309)
162. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA: In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control Release 112(1), 26-34 (2006).
163. Elamanchili P, Diwan M, Cao M, Samuel J: Characterization of poly(d,l-lactic-coglycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 22(19), 2406-2412 (2004). (Pubitemid 38757337)
164. Aline F, Brand D, Pierre J et al.: Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 27(38), 5284-5291 (2009).
165. Lisziewicz J, Calarota SA, Lori F: The potential of topical DNA vaccines adjuvanted by cytokines. Expert Opin. Biol. Ther. 7(10), 1563-1574 (2007). (Pubitemid 47603082)
166. Lisziewicz J, Kelly L, Lori F: Topical DermaVir vaccine targeting dendritic cells. Curr. Drug Deliv. 3(1), 83-88 (2006).
167. Lori F, Trocio J, Bakare N, Kelly LM, Lisziewicz J: DermaVir, a novel HIV immunisation technology. Vaccine 23(17-18), 2030-2034 (2005). (Pubitemid 40341422)
168. Calarota SA, Dai A, Trocio JN, Weiner DB, Lori F, Lisziewicz J: IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine 26(40), 5188-5195 (2008).
169. Cristillo AD, Lisziewicz J, He L et al.: HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 366(1), 197-211 (2007). (Pubitemid 47314400)
170. Dadachova E, Casadevall A: Radioimmunotherapy of infectious diseases. Semin. Nucl. Med. 39(2), 146-153 (2009).
171. Mason RD, Alcantara S, Peut V et al.: Inactivated simian immunodeficiency virus-pulsed autologous fresh blood cells as an immunotherapy strategy. J. Virol. 83(3), 1501-1510 (2009).
172. Pugach P, Kuhmann SE, Taylor J et al.: The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 321(1), 8-22 (2004). (Pubitemid 38368098)
173. Touzet O, Philips A: Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation. AIDS 24(10), 1437-1447 (2010).
174. Zhang HS, Zhou Y, Wu MR, Zhou HS, Xu F: Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD+-dependent SIRT1 activity. Life Sci. 85(13-14), 484-489 (2009).
175. Read SW, DeGrezia M, Ciccone EJ et al.: The effect of leflunomide on cycling and activation of T cells in HIV-1-infected participants. PLoS One 5(8), E11937 (2010).
176. ClinicalTrials.gov http://clinicaltrials.gov/(Accessed 6 September 2010)